The gene OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) is mapped to human chromosome Xq13.1. The encoded protein has 13.5 tetratricopeptide-repeats (TPR) and a globular catalytic domain.
Synonyms: Anti-FLJ23071; Anti-HRNT1; Anti-MGC22921; Anti-O-GLCNAC; Anti-O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)
MDL Number: MFCD07370422
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) is responsible for addition of O-linked N-acetylglucosamine (O-GlcNAc) to the serine/threonine residues in protein of interest. It is needed for O-GlcNAcylation of RNA polymerase II. Absence of OGT reduces transcription and pol II promoter occupancy. OGT gene is upregulated in breast cancer tissues, colon cancer, lung cancer and laryngeal cancer. It might be associated with tumorigenesis and metastasis.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC